Rationale: In recent decades, diagnosis and treatment recommendations for idiopathic
pulmonary fibrosis (IPF) have changed. In Korea, the average life expectancy has increased …

Recently updated guidelines have provided revised recommendations, based on the
GRADE criteria, for the diagnosis and pharmacological and non-pharmacological …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that kills nearly 40,000 US
citizens annually and has a median survival that has been estimated at 3 to 5 years. Most …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …

The past decade has been extraordinarily fruitful for the study and management of idiopathic
pulmonary fibrosis (IPF). The ability of physicians to make a clear and definitive diagnosis …

Objective Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal disease, with
very few therapeutic options. Given a paucity of qualitative research to the perspective of …

Introduction: Idiopathic pulmonary fibrosis (IPF) treatment was revolutionized by the advent
of two novel antifibrotics, nintedanib and pirfenidone. However, neither is a panacea and …

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease of unknown
cause. Approximately 5,000 people are diagnosed with IPF in the UK every year. People …

The Pulmonary Fibrosis Foundation was recently requested “to sponsor a leadership summit
to discuss appropriate endpoints for future Phase 3 trials in IPF,” the results of which have …